{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:16:07Z","timestamp":1788066967813,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,8]],"date-time":"2027-08-08T00:00:00Z","timestamp":1817683200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["GM138722"],"award-info":[{"award-number":["GM138722"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["GM150502"],"award-info":[{"award-number":["GM150502"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154404","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:36:23Z","timestamp":1786116983000},"page":"154404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PIP4K2A depletion suppresses AKT signaling and enhances chemotherapy sensitivity in T-cell lymphoblastic lymphoma cells"],"prefix":"10.1016","volume":"832","author":[{"given":"Song","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-3468","authenticated-orcid":false,"given":"Ya","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154404_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The genetics and mechanisms of T cell acute lymphoblastic leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154404_bib2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2643-3230.BCD-25-0206","article-title":"Genomic insights into the biology of T-lineage acute lymphoblastic leukemia","volume":"7","author":"P\u00f6l\u00f6nen","year":"2026","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.bbrc.2026.154404_bib3","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41375-025-02599-2","article-title":"T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments","volume":"39","author":"Buckley","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154404_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","article-title":"Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia","volume":"8","author":"Shimony","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2026.154404_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-025-02529-2","article-title":"Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action","volume":"39","author":"Hormann","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154404_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/36621","article-title":"A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate","volume":"390","author":"Rameh","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154404_bib7","doi-asserted-by":"crossref","first-page":"20292","DOI":"10.1074\/jbc.273.32.20292","article-title":"A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase IIgamma) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals","volume":"273","author":"Itoh","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154404_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/BJ20130488","article-title":"Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization","volume":"454","author":"Clarke","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2026.154404_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1873-3468.14237","article-title":"Expanding role of PI5P4Ks in cancer: a promising druggable target","volume":"596","author":"Arora","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2026.154404_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41573-022-00582-5","article-title":"Beyond PI3Ks: targeting phosphoinositide kinases in disease","volume":"22","author":"Burke","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.154404_bib11","article-title":"25 years of PI5P","volume":"11","author":"Rameh","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2026.154404_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ceb.2021.01.012","article-title":"Emerging cell biological functions of phosphatidylinositol 5 phosphate 4 kinase","volume":"71","author":"Raghu","year":"2021","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154404_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-9822(00)00002-6","article-title":"Tumor spectrum analysis in p53-mutant mice","volume":"4","author":"Jacks","year":"1994","journal-title":"Curr. Biol. : CB"},{"key":"10.1016\/j.bbrc.2026.154404_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cell.2013.09.057","article-title":"Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors","volume":"155","author":"Emerling","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154404_bib15","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1101\/gad.252148.114","article-title":"The evolution of thymic lymphomas in p53 knockout mice","volume":"28","author":"Dudgeon","year":"2014","journal-title":"Gene Dev."},{"key":"10.1016\/j.bbrc.2026.154404_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.115952","article-title":"PIP4K2A\/2B inhibitor suppresses tumor growth in a xenograft model of NSCLC","volume":"29","author":"He","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2026.154404_bib17","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","article-title":"An optimized microRNA backbone for effective single-copy RNAi","volume":"5","author":"Fellmann","year":"2013","journal-title":"Cell Rep."},{"issue":"Pt 3","key":"10.1016\/j.bbrc.2026.154404_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/bj3460587","article-title":"Nuclear targeting of the beta isoform of type II phosphatidylinositol phosphate kinase (phosphatidylinositol 5-phosphate 4-kinase) by its alpha-helix 7","volume":"346","author":"Ciruela","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2026.154404_bib19","article-title":"Pharmacological inhibition of PI5P4K\u03b1\/\u03b2 disrupts cell energy metabolism and selectively kills p53-null tumor cells","volume":"118","author":"Chen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154404_bib20","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1021\/acs.jmedchem.1c01245","article-title":"Discovery and characterization of the potent and highly selective 1,7-Naphthyridine-Based inhibitors BAY-091 and BAY-297 of the kinase PIP4K2A","volume":"64","author":"Wortmann","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154404_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1107\/S2059798326003773","article-title":"Structural basis for high-affinity inhibitor binding to lipid kinases PIP4K2A and PIP4K2B","volume":"82","author":"He","year":"2026","journal-title":"Acta crystallograp. Section D, Struct. Biol."},{"key":"10.1016\/j.bbrc.2026.154404_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/onc.2014.77","article-title":"A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival","volume":"34","author":"Jude","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154404_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202302364","article-title":"Targeting the dark lipid kinase PIP4K2C with a potent and selective binder and degrader","volume":"62","author":"Teng","year":"2023","journal-title":"Angewandte Chemie (International ed. in English)"},{"key":"10.1016\/j.bbrc.2026.154404_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115027","article-title":"Development of potent and selective degraders of PI5P4K\u03b3","volume":"247","author":"Ji","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154404_bib25","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.celrep.2019.04.070","article-title":"PIP4Ks suppress insulin signaling through a catalytic-independent mechanism","volume":"27","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2026.154404_bib26","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.1320265111","article-title":"Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells","volume":"111","author":"Hoshii","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2601168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2601168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T04:22:05Z","timestamp":1788063725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2601168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S0006291X2601168X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154404","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PIP4K2A depletion suppresses AKT signaling and enhances chemotherapy sensitivity in T-cell lymphoblastic lymphoma cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154404"}}